GSK's Hibsago Gets US FDA Approval for Chronic Hepatitis B

GSK secured global rights to HMPL-A830, paying Hutchmed $110M upfront with potential $1.19B milestones. FDA approved Hibsago for chronic hepatitis B, licensed from Ionis. GSK aims to offset HIV patent expiries with drugs like Hibsago, projecting over £2B peak sales.

The US FDA approved GSK's Hibsago for chronic hepatitis B in adults without cirrhosis. The six-month treatment, combined with nucleos(t)ide analogue therapy, achieved a 19% functional cure rate in phase III trials, compared to 0% with placebo, according to the company.

GSK's Hibsago (bepirovirsen) received FDA approval for chronic hepatitis B treatment. The drug, with a 19% functional cure rate in trials, is for adults without cirrhosis who meet specific criteria. GSK licensed it from Ionis Pharmaceuticals and expects further regulatory decisions soon. Chronic hepatitis B affects 1.7 million people in the US.

GSK's (GSK) Hibsago (bepirovirsen) received FDA approval for treating chronic hepatitis B in adults without cirrhosis. The drug showed 19-26% functional cure rates in trials. It's approved in the U.S. and Japan, with regulatory submissions pending elsewhere. Chronic hepatitis B affects 1.7M in the U.S. and 240M globally.

GSK received US FDA approval for its chronic hepatitis B treatment, Hibsago. The company's shares have shown recent gains. Additionally, Hutchmed (China) closed a licensing deal with GSK for another drug candidate, HMPL-A830.

GSK's Hibsago (bepirovirsen) received FDA approval for chronic hepatitis B in adults without cirrhosis. The approval is based on Phase 3 trial results showing a 19% functional cure rate. GSK licensed the drug from Ionis and is pursuing regulatory submissions globally. GSK's stock closed at $50.63, up 2.37%.